Iovance Biotherapeutics Inc
(NAS:IOVA)
$
9.4
0.28 (3.07%)
Market Cap: 2.86 Bil
Enterprise Value: 2.55 Bil
PE Ratio: 0
PB Ratio: 3.70
GF Score: 39/100 Iovance Biotherapeutics Inc at Cowen Immuno-Oncology Next Summit (Virtual) Transcript
Nov 15, 2021 / 08:45PM GMT
Release Date Price:
$19.59
(-7.02%)
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
The next company at our conference is Iovance Biotherapeutics. And it's my pleasure to host Fred, the Interim CEO; and Friedrich, the Chief Medical Officer. Thanks both of you for joining us.
Frederick G. Vogt
Iovance Biotherapeutics, Inc. - Interim President, CEO, General Counsel & Corporate Secretary
Thanks, Boris.
Questions & Answers
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
So I'd like to discuss the issue that I think is at the top of all investors' mind, and that's the regulatory assay. Can you just walk us through the assay development issues that arose during the regulatory review and kind of what stage of validation work you currently are in for this assay?
Frederick G. Vogt
Iovance Biotherapeutics, Inc. - Interim President, CEO, General Counsel & Corporate Secretary
Sure. So during the prior regulatory
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot